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BASIC SCIENCES
Galectin-3 Identifies a Subset of Macrophages 
With a Potential Beneficial Role in Atherosclerosis
Karina Di Gregoli, Michelle Somerville, Rosaria Bianco, Anita C. Thomas, Aleksandra Frankow, Andrew C. Newby, Sarah J. George, 
Christopher L. Jackson, Jason L. Johnson
OBJECTIVE: Galectin-3 (formerly known as Mac-2), encoded by the LGALS3 gene, is proposed to regulate macrophage 
adhesion, chemotaxis, and apoptosis. We investigated the role of galectin-3 in determining the inflammatory profile of 
macrophages and composition of atherosclerotic plaques.
APPROACH AND RESULTS: We observed increased accumulation of galectin-3–negative macrophages within advanced human, 
rabbit, and mouse plaques compared with early lesions. Interestingly, statin treatment reduced galectin-3–negative macrophage 
accrual in advanced plaques within hypercholesterolemic (apolipoprotein E deficient) Apoe−/− mice. Accordingly, compared with 
Lgals3+/+:Apoe−/− mice, Lgals3−/−:Apoe−/− mice displayed altered plaque composition through increased macrophage:smooth 
muscle cell ratio, reduced collagen content, and increased necrotic core area, characteristics of advanced plaques in humans. 
Additionally, macrophages from Lgals3−/− mice exhibited increased invasive capacity in vitro and in vivo. Furthermore, loss of 
galectin-3 in vitro and in vivo was associated with increased expression of proinflammatory genes including MMP (matrix 
metalloproteinase)-12, CCL2 (chemokine [C-C motif] ligand 2), PTGS2 (prostaglandin-endoperoxide synthase 2), and IL 
(interleukin)-6, alongside reduced TGF (transforming growth factor)-β1 expression and consequent SMAD signaling. 
Moreover, we found that MMP12 cleaves macrophage cell-surface galectin-3 resulting in the appearance of a 22-kDa 
fragment, whereas plasma levels of galectin-3 were reduced in Mmp12−/−:Apoe−/− mice, highlighting a novel mechanism where 
MMP12-dependent cleavage of galectin-3 promotes proinflammatory macrophage polarization. Moreover, galectin-3–positive 
macrophages were more abundant within plaques of Mmp12−/−:Apoe−/− mice compared with Mmp12+/+:Apoe−/− animals.
CONCLUSIONS: This study reveals a prominent protective role for galectin-3 in regulating macrophage polarization and invasive 
capacity and, therefore, delaying plaque progression.
VISUAL OVERVIEW: An online visual overview is available for this article.
Key Words: atherosclerosis ◼ chemotaxis ◼ fibrosis ◼ interleukin-6 ◼ macrophages
Atherosclerosis is a major cause of cardiovascular disease. The majority of myocardial infarctions and strokes originate from artery occlusion precipitated 
through atherosclerotic plaque instability and rupture.1 
Despite the long-standing notion that atherosclerosis is 
solely a cholesterol storage disease, recent clinical and 
experimental findings support a contemporaneous criti-
cal role for inflammation in atherosclerosis,2 a hypothesis 
further strengthened by the outcome of the CANTOS trial 
(Canakinumab Antiinflammatory Thrombosis Outcome 
Study), which showed a reduction in adverse cardiovas-
cular events in patients treated with an antibody against 
IL (interleukin)-1B.3 In humans, atherosclerotic plaque 
formation and progression occur over many decades 
and involve monocyte/macrophage accumulation within 
the arterial wall, macrophage foam cell formation, con-
sequent necrotic/lipid core establishment, and expan-
sion, alongside vascular remodeling and extracellular 
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matrix degradation.4,5 Accordingly, monocytes/macro-
phages are proposed to play a central role in disease 
initiation, development, and destabilization.5 Accumulat-
ing evidence from histological examination of human 
plaques and animal studies has implied that macrophage 
number and their phenotypic heterogeneity influence 
plaque stability and disease outcome.6,7 In vitro studies 
of macrophage polarization led to a simplified view that 
M1 macrophages (classically activated) promote inflam-
mation and plaque instability, whereas M2 macrophages 
(alternatively activated) foster plaque stability through 
promoting fibrosis and resolving inflammation. However, 
macrophage phenotypic heterogeneity within plaques 
is likely to be more intricate because macrophages are 
under the influence of wide-ranging signals and diverse 
microenvironments.8–10
Galectin-3, also known as Mac-2, is a β-galactoside–
binding lectin encoded by the LGALS3 gene. It presents 
a carbohydrate recognition–binding domain that enables 
its specific binding to β-galactosides and a repetitive 
collagen-like sequence, which serves as a substrate for 
metalloproteinases.11 Galectin-3 has been described as 
a pleiotropic molecule,11 which is expressed on the cell 
membrane, within the cytoplasm or the nucleus, and has 
been proposed to function as a mediator of inflamma-
tion, fibrosis, cell adhesion, apoptosis, and chemotaxis. 
Galectin-3 is highly expressed in macrophages within 
human and murine atherosclerotic plaques12–14 and has 
been proposed to exert a deleterious role on plaque 
progression through amplification of the inflammatory 
response.13 Conversely, others have suggested a benefi-
cial effect through modulation of the inflammatory profile 
of macrophages, potentially toward a profibrotic and anti-
inflammatory phenotype,15 although this has not been 
fully established. Similarly, in vivo studies relying on ani-
mal models of atherosclerosis using lesion initiation and 
size as primary end points have supported both pro- and 
antiatherosclerotic roles for galectin-3.14,16,17 However, 
plaque composition and phenotype were not directly 
assessed in the aforementioned studies, and, therefore, 
the role of galectin-3 in plaque composition rather than 
size remains uncertain.
Abundant literature supports a profibrotic role of 
galectin-3 in a wide range of pathologies and suggests 
a plausible protective role for this modulatory protein 
in advanced atherosclerosis through supporting plaque 
stability. Accordingly, galectin-3 can mediate produc-
tion of profibrotic factors and collagen accumulation 
in a variety of diseases.11 Indeed, galectin-3 expres-
sion is abnormally increased in fibrotic patients18–21 
while galectin-3 inhibition can attenuate cardiac fibro-
sis in rat and mouse models of heart failure.22 In the 
present study, we investigated the role of galectin-3 
in regulating macrophage invasion and consequent 
modulation of atherosclerotic plaque phenotype. Our 
results identify galectin-3 as a significant regulator of 
plaque composition, in part, through inhibition of mac-
rophage inflammatory polarization. Consistent with this, 
galectin-3 deficiency resulted in an enrichment of pro-
inflammatory markers including MMP (matrix metallo-
proteinase)-12, which we reveal can cleave galectin-3 
and shift macrophages from an anti-inflammatory pro-
fibrotic phenotype to one with proinflammatory charac-
teristics. We also show that, contrary to stable plaques, 
galectin-3–negative macrophages populate advanced 
plaques with histological features consistent with 
clinically relevant lesions in humans. Our findings lend 
further support to MMP12 as a pertinent therapeutic 
Nonstandard Abbreviations and Acronyms
αSMactin alpha-smooth muscle actin
CCL2 chemokine (C-C motif) ligand 2
CD cluster of differentiation
CSF colony stimulating factor
CX3CL1 chemokine ligand 1
GM-CSF  granulocyte/macrophage colony stimu-
lating factor
IL interleukin
LGALS3 lectin, galactoside-binding, soluble, 3
M-CSF macrophage colony stimulating factor
MCP-1 monocyte chemoattractant protein-1
MMP matrix metalloproteinase
MRC1 mannose receptor C-type 1
PBMC peripheral blood mononuclear cell
PCR polymerase chain reaction
PTGS2 prostaglandin-endoperoxide synthase 2
TGF transforming growth factor
TIMP tissue inhibitor of metalloproteinase
TNFA tumor necrosis factor-alpha
VSMC vascular smooth muscle cell
Highlights
• Galectin-3 expression is restricted to a subset of 
macrophages within atherosclerotic plaques, which 
is further reduced during plaque progression.
• Galectin-3 deficiency promotes formation of athero-
sclerotic plaques with a deleterious shift in cellular 
and extracellular characteristics.
• Macrophage galectin-3 expression suppresses 
polarization toward a proinflammatory phenotype.
• Galectin-3 positively regulates TGF (transforming 
growth factor)-β signaling and retards macrophage 
invasion.
• Macrophage galectin-3 can be cleaved by MMP 
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target for the prevention of clinical atherosclerosis 
and suggest that promoting galectin-3 expression may 
also represent an effective strategy to counter the 
actions of proinflammatory macrophages during plaque 
progression.
MATERIALS AND METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
Human Coronary Samples
Coronary artery segments were collected from cadaveric heart 
donors from the Bristol Valve Bank and incorporated into the 
Bristol Coronary Artery Biobank under National Research 
Ethics Service approval (08/H0107/48). The patients with his-
tologically defined stable and unstable plaques (n=14/group) 
were of average age 56±2 and 59±2 years, respectively, and a 
9/5 male–to-female ratio, as described previously.23 Coronary 
artery plaques were histologically classified as stable or unsta-
ble through evaluation of intraplaque cellular content, lipid/
necrotic core size, and collagen amount, as shown to be effec-
tive delineators in human coronary plaque phenotyping4,24 and 
as described previously.23,25 Serial paraffin sections were immu-
nolabeled with a CD (cluster of differentiation)-68 antibody to 
detect macrophages or αSMactin (alpha-smooth muscle actin) 
to distinguish vascular smooth muscle cells (VSMCs), along-
side a galectin-3 antibody and the cells quantified.
Animals
Male and female New Zealand White rabbits were fed a 1% 
cholesterol-enriched diet for 4 or 8 weeks to induce aortic ath-
erosclerosis. Atherosclerotic plaques from 4-to-8 week high 
fat–fed animals were classified as early or advanced lesions, 
respectively, as described previously.26 As a model of athero-
sclerotic plaque stabilization, animals were fed for 8 weeks with 
a cholesterol-enriched diet (containing 21% [wt:wt] pork lard 
and supplemented with 0.15% [wt:wt] cholesterol; Special Diet 
Services, Witham, United Kingdom) and subsequently fed for 8 
weeks with a standard laboratory diet. Mice homozygous null for 
the Apoe gene (Apoe −/−) on a 71% C57BL/6J, 29% 129/SvJ 
background, were derived from a closed outbred colony housed 
within the Animal Unit of the University of Bristol. Apoe −/−  
mice were crossed with galectin-3–deficient (Lgals3−/−) mice 
to generate Lgals3−/−:Apoe−/− double knockout mice, as well 
as their relevant age-, strain-, and sex-matched Lgals3+/+:A
poe−/− littermate controls. A similar approach was used to gen-
erate Mmp12−/−:Apoe−/− double knockout mice, as well as their 
relevant age-, strain-, and sex-matched Mmp12+/+:Apoe −/− lit-
termate controls, as described previously and using Mmp12−/− 
mice on a 129-strain background.27 In both instances, genomic 
DNA was extracted from tail tips for genotyping by polymerase 
chain reaction (PCR). To assess effects of Lgals3 (galectin-3) 
or Mmp12 gene deficiency on atherosclerotic plaque forma-
tion within the brachiocephalic arteries of Apoe−/− mice, male 
animals at the age of 8 to 10 weeks were fed a high-fat diet for 
8 weeks, as demonstrated previously.27 To evaluate the effects 
of statin treatment on plaque macrophage galectin-3 expres-
sion, pravastatin was administered in the drinking water to male 
Apoe−/− mice at a dose of 40 mg/kg of body weight per day 
for 9 weeks, commencing at the same time as high-fat diet 
feeding, alongside a littermate control group, which received 
drinking water alone, as described previously.28
The housing and care of the animals and all the procedures 
used in these studies were performed in accordance with the 
guidelines and regulations of the University of Bristol and the 
UK Home Office. The investigation conforms to the Guide for 
the Care and Use of Laboratory Animals published by the US 
National Institutes of Health (publication No. 85-23, revised 
1996). Adherence to the ARRIVE guidelines (Animal Research: 
Reporting of In Vivo Experiments)29 for the reporting of animal 
in vivo experiments was also followed, as was the guidance 
given within the ATVB Council Statement in consideration of 
sex differences in design and reporting of experimental arterial 
pathology studies.30 As demonstrated previously,28 atheroscle-
rotic lesions develop more rapidly in the brachiocephalic arter-
ies of male mice compared with females, and, therefore, only 
male animals were used in these studies. To ensure studies 
were adequately powered to detect a 30% change in plaque 
area, and compositional parameters including macrophage 
(CD68 immunopositivity) and smooth muscle cell (αSMactin 
immunopositivity) content, group sizes in excess of 13 animals 
were used for gene knockout studies and at least 10 animals 
for statin treatment.
Termination
Animals were anaesthetized by intraperitoneal injection of 
sodium pentobarbitone, before exsanguination by perfusion via 
the abdominal aorta with PBS at a constant pressure of 100 
mm Hg, with outflow through the incised jugular veins. This was 
followed by constant pressure perfusion with 10% formalin.
Histology, Plaque Morphometrics, and 
Histological Analyses
The American Heart Association guidelines for experimental 
atherosclerosis studies were used31 and applied to the asso-
ciated histological analyses within this study. Brachiocephalic 
arteries were embedded in paraffin wax, and histological sec-
tions were cut at 3-µm thickness from the proximal region 
of the ascending aortic bifurcation as described previously.28 
Sections were stained using Miller elastin/van Gieson for the 
detection of elastin, picrosirius red for fibrillar collagens, and 
hematoxylin and eosin for necrotic core evaluation. For immu-
nohistochemistry, sections were subjected to antigen retrieval 
after dewaxing and rehydration, blocked with 5% horse serum 
or Image-iT FX Signal Enhancer (Invitrogen, Life Technologies, 
Paisley, United Kingdom) before addition of the appropriate pri-
mary antibody (Major Resources Table in the Data Supplement) 
and incubated overnight at 4°C. For brightfield analysis, sec-
tions were subsequently incubated with the relevant species 
biotinylated secondary antibody, followed by extravidin/DAB 
(3,3'-diaminobenzidine) chromogen detection. In the case 
of fluorescence analysis, a relevant species secondary anti-
body conjugated with a desired DyLight fluorophore (Vector 
Laboratories, Peterborough, United Kingdom) was used.
Dual immunohistochemistry was performed by incubating 
sections with 2 appropriate primary antibodies simultaneously 
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4°C. After washing, sections were incubated in the dark with 
DyLight-488 conjugated (for galectin-3) and DyLight-594 
conjugated (for RAM [rabbit atherosclerosis macrophage]-11 
in rabbit and CD68 in mouse) secondary antibodies (Vector 
Laboratories) for 1 hour at room temperature. Sections were 
then washed and mounted with ProLong Gold antifade reagent 
containing DAPI (4′,6-diamidino-2-phenylindole; Invitrogen, 
Life Technologies) to label nuclei. In all instances, a negative 
control where the primary antibody was replaced with the rel-
evant species IgG at the same dilution was always (Figure I in 
the Data Supplement) included, and the cells within the entire 
plaque cross section were counted under ×20 magnification. 
Positive cells were counted and expressed as a percentage of 
total nucleated cells.
For sectioning and associated staining with each marker, 
3 to 5 cross sections (each 15 µm apart) from the proximal 
brachiocephalic artery were quantified per mouse, with n=10 
to 13 mice per group across all experimental groups. Analysis 
was performed using a computerized image analysis program 
(Image Pro Plus; DataCell, Maidenhead, United Kingdom). 
The lengths of the internal and external elastic lamellae were 
recorded by image analysis. These were used to derive the total 
vessel area and the lumen-plus-plaque area, by assuming them 
to be the circumferences of perfect circles. Plaque area was 
measured directly and was subtracted from the area enclosed 
by the internal elastic lamina to derive the lumen area. A vulner-
ability index was calculated as described previously23,32 by divid-
ing the percentage of plaque area occupied by macrophages 
(CD68 immunopositivity) and necrotic core, by that of VSMCs 
(αSMactin immunopositivity) and collagen, with a higher num-
ber implying a deleterious shift in cellular and extracellular 
components. We acknowledge that recent murine cell-lineage 
experiments33,34 have demonstrated limitations in using CD68 
and SM actin as macrophage and VSMC markers, respectively, 
within mouse atherosclerotic lesions.
Peripheral Blood Mononuclear Cell Isolation
Peripheral blood from experimental female and male mice was 
collected by cardiac puncture in the presence of heparin as an 
anticoagulant. Blood (≈1 mL per mouse) was pooled accord-
ing to the experimental requirements and diluted with Dulbecco 
PBS without calcium and magnesium (Lonza) 1× (ratio 1:1). 
Human peripheral blood mononuclear cells (PBMCs) were iso-
lated from whole blood of healthy donors, which were collected 
under South West 4 Research Ethics Committee reference 
09/H0107/22 and diluted in PBS without calcium and magne-
sium (Lonza) 1× (ratio 1:1). Diluted samples were subjected to 
density gradient separation on Ficoll Paque Plus (ratio 1:1; GE 
Healthcare Life Sciences, Buckinghamshire, United Kingdom) 
and centrifuged. After centrifugation, the PBMC layer was col-
lected and washed in Hanks balanced salt sodium with phenol 
red without calcium and magnesium (Lonza).
Monocyte Isolation and Macrophage Maturation
PBMCs were resuspended in Roswell Park Memorial Institute 
(RPMI) 1640 supplemented with gentamicin (8 µg/mL), 
penicillin and streptomycin (100 µg/mL, respectively), 1% 
L-glutamine, and 10% FCS (referred to here after as RPMI/
FCS media) and placed in 6-well culture plates (surface area, 
5×105 per well), in 12-well culture plates (2.5×105 per well) 
or in 8-well multichamber Millicell EZ slides (Merck Millipore, 
Watford, United Kingdom; 5×104 per well), depending on the 
experimental protocol. After 2 hours, cells were washed in 
RPMI/FCS media to remove nonadherent cells and incubated 
at 37°C at 5% CO2. To differentiate blood-derived monocytes 
into macrophages, monocytes were cultured for the first 4 days 
with RPMI/FCS plus 40 ng/mL recombinant mouse/human 
M-CSF (macrophage colony stimulating factor; Miltenyi Biotec, 
Surrey, United Kingdom) and then for additional 3 days with 
20 ng/mL recombinant M-CSF (Miltenyi Biotec) and 20 ng/
mL recombinant mouse/human GM-CSF (granulocyte/mac-
rophage colony stimulating factor; Miltenyi Biotec) at 37°C to 
generate proinflammatory macrophages or M-CSF alone to 
produce anti-inflammatory macrophages.
In Vitro Monocyte/Macrophage Invasion Assay
Monocyte/macrophage accumulation (considered to be a 
surrogate for steady-state invasion) in vitro was assessed 
using Matrigel-coated transwell inserts (Merck Millipore) as 
described previously.32 Transwell inserts containing 8-µm pore 
membranes were coated with 25 µL/well Basement Membrane 
Matrix Lactose-Dehydrogenase-Elevating-Virus-Free (Matrigel; 
BD Biosciences, Oxford, United Kingdom). Purified mouse 
recombinant galectin-3 (5 nM; R&D Systems, Abingdon, 
United Kingdom) was added to the Matrigel of the appropriate 
inserts. Monocyte-derived macrophages (detached by trypsin) 
were resuspended in RPMI/FCS (100 µL; 1×105 cells) and 
then added to the upper portion of the transwell. RPMI/FCS 
(600 µL) supplemented with 30 ng/mL mouse recombinant 
MCP-1 (monocyte chemoattractant protein-1; CCL2 [chemo-
kine (C-C motif) ligand 2]) and 30 ng/mL mouse recombinant 
fractalkine (CX3CL1 [chemokine ligand 1]; R&D Systems) was 
placed in the lower wells to induce transmigration/invasion. 
Transwells were incubated for 48 hours, and then cells on both 
the upper and lower surface of the membrane were fixed with 
3% paraformaldehyde in PBS, subjected to immunocytochem-
istry for CD68 and mounted with polyvinylpyrrolidone. Cells 
were counted in six ×20 magnification fields, and the num-
ber of migrated/invaded cells expressed as a percentage of 
total cells. The assay and associated statistical analysis were 
performed on cells retrieved from 4 separate donors and sub-
jected to paired analysis.
In Vivo Monocyte/Macrophage Invasion Assay
Ten-week-old, normal laboratory diet–fed male Lgals3+/+:
Apoe−/− mice and Lgals3−/−:Apoe−/− mice (n=6/group) were 
anesthetized by inhalation with isofluorane, and Matrigel 
(BD Biosciences) infused sponges placed under the dorsal 
skin for 11 days to permit monocyte/macrophage accumula-
tion as described previously.32 Mice were then returned to a 
normal laboratory diet for a further 11 days and then termi-
nated and the sponges retrieved and fixed in 10% formalin 
for histological analysis. Fixed sponges were then processed 
and wax-embedded before eight 3-µm sections (each 15 µm 
apart) were taken from each bisected sponge and subjected 
to immunohistochemistry for CD68. The number of CD68-
positive cells (classified as macrophages) were quantified 
within ten ×20 magnification fields selected by their proximity 
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Gene Silencing
Fully differentiated macrophages (7 days in culture) at 40% to 
60% confluence were transfected with 50-nM small interfer-
ing (si)-galectin-3 (Qiagen, Ltd, Crawley West Sussex, United 
Kingdom) or with AllStars Negative Control siRNA (Qiagen, 
Ltd) using Lipofectamine RNAi-MAX as small interfering RNA 
transfection reagent (Invitrogen, Life Technologies) according 
to the manufacturer’s protocol. Forty-eight hours post-transfec-
tion, cells were collected for further analysis.
RNA Extraction and Reverse Transcription PCR
The Qiagen miRNeasy kit was used for total RNA extraction 
(Qiagen, Ltd) according to the manufacturer’s protocol. RNA 
samples were quantified with a NanoDrop ND-1000 spec-
trophotometer (LabTech International, Ringmer, East Sussex, 
United Kingdom). The miScript Reverse Transcription Kit 
(Qiagen, Ltd) was used to obtain equal amounts of cDNA from 
RNA samples; sample preparation and reaction mix was per-
formed in accordance with the manufacturer’s instructions. 
Samples were incubated first at 42°C for 60 minutes and 
then at 95°C for 3 minutes. The cDNA obtained was stored 
at −80°C.
Real-Time Quantitative PCR
QuantiTect SYBR Green PCR Kit (Qiagen, Ltd) was used to 
carry out quantitative PCR using a Roche LightCycler 480 
(Roche). Coding DNA was amplified using 4 ng of cDNA sam-
ple in accordance with the manufacturer’s instructions. Primers 
were designed using a National Center for Biotechnology 
Information (NCBI) web-based tool and ordered from Sigma 
(Major Resources Table in the Data Supplement). Denaturation 
(melt) curve analysis after real-time quantitative PCR cycling 
was always performed to ensure the presence of a single dis-
tinct peak real-time quantitative PCR, and associated statisti-
cal analysis was performed on cells retrieved from 4 separate 
donors and subjected to paired analysis.
Western Blotting
SDS lysis buffer was used to extract macrophage proteins, and 
total protein concentration was measured using a bicincho-
ninic acid protein assay kit (Pierce). Equal protein concentra-
tions were loaded and electrophoresed on 4% to 12% gradient 
gels (Mini-PROTEAN TGX Stain-Free Precast Gels; Bio-Rad, 
Watford, United Kingdom) and transferred to 0.2-µm nitrocel-
lulose membranes. Blots were blocked with 5% (w/v) skimmed 
milk powder and incubated overnight at 4°C with anti–galec-
tin-3, anti–active TGF (transforming growth factor)-β1, anti–
pSMAD-3, or anti-MMP12 antibody (Major Resources Table 
in the Data Supplement) diluted in SignalBoost Solution 1 
(Merck Millipore). Primary antibodies were detected using spe-
cies-relevant HRP-conjugated secondary antibodies diluted 
in SignalBoost Solution 2 (Merck Millipore) and enhanced 
Luminata Forte chemiluminescence reagent (Merck Millipore). 
Optical density of bands was quantified using Gel Doc XR+ 
Gel Documentation System (Bio-Rad) and normalized to sam-
ple total protein content (whole lane) assessed using Bio-Rad 
stain-free technology and present the most intense band within 
the representative figures, which are referred to as loading 
control.
Cleavage Assay
Human recombinant MMP12 (R&D Systems) was activated 
by 4 hours of incubation at 37°C with 1 mmol/L 4-amino-
phenylmercuric acetate, in 1× Zymogram Development Buffer 
(Bio-Rad). Subsequently, 200 nM of human recombinant galec-
tin-3 (R&D Systems) was incubated with either nonactivated 
pro-MMP12 (100 nM), active MMP12 (100 nM), or active 
MMP12 (100 nM) plus human recombinant TIMP (tissue 
inhibitor of metalloproteinase)-3 (10 nmol/L) in 1× Zymogram 
Development Buffer (Bio-Rad). Samples were incubated at 
37°C for 60 minutes; the reaction was then stopped by plac-
ing samples on ice. Galectin-3 cleavage was then assessed by 
Western blotting. To evaluate whether MMP inhibition retards 
galectin-3 cleavage, macrophages were incubated in serum-
free media with or without recombinant TIMP3 (10 nM) or the 
broad-spectrum MMP inhibitor Batimastat, BB94 (20 nM). 
After 24 hours of incubation at 37°C, conditioned media were 
collected and the presence of cleaved galectin-3 (fragment of 
22 kDa) assessed by Western blotting.
Enzyme-Linked Immuno-Sorbent Assay
Mouse plasma levels of galectin-3 were quantitatively 
assessed using the Galectin-3 Mouse SimpleStep enzyme-
linked immuno-sorbent assay (ELISA) kit (ab203369; Abcam, 
Cambridge, United Kingdom) in accordance with the manufac-
turer’s protocol. Briefly, diluted plasma samples (6.25%) were 
incubated with antibody cocktail (ratio 1:1) in the provided 
ELISA plate for 1 hour at room temperature on a plate shaker 
(400 rpm). After 3 washes with 1× washing buffer (provided), 
100 µL of TMB (3,3′,5,5′-tetramethylbenzidine) substrate was 
added to each well and the plate immediately transferred to 
a plate reader and substrate development recorded kineti-
cally (600 nm/12 cycles/read every 50″). Condition media 
from human macrophage were quantitatively assessed for lev-
els of IL-6 and MCP-1 using Quantikine ELISA Kits (D6050 
and CDP00, respectively; Bio-Techne) in accordance with the 
manufacturer’s protocol. Monocyte-derived macrophages (n=4 
independent donors) were cultured for 7 days and then trans-
fected with 50-nM small interfering (si)-galectin-3 (Qiagen, 
Ltd) or with AllStars Negative Control siRNA (Qiagen, Ltd) 
using Lipofectamine RNAi-MAX as small interfering RNA 
transfection reagent (Invitrogen, Life Technologies) according 
to the manufacturer’s protocol. Forty-eight hours post-transfec-
tion, the condition media were collected and analyzed. Briefly, 
samples were incubated with antibody cocktail in the provided 
ELISA plate for 2 hours at room temperature. After 3 washes 
with 1× washing buffer (provided), 200 µL of substrate solu-
tion was added to each well and incubated for 20 minutes at 
room temperature protecting from light. Fifty microliters of Stop 
solution was then added to each well and mixed well. The plate 
was then transferred to a plate reader and read at 450 nm on 
a microplate reader.
Flow Cytometry
PBMCs were isolated from whole blood of healthy donors and 
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1:1). Diluted samples were subjected to density gradient separa-
tion on Ficoll Paque Plus (ratio 1:1; GE Healthcare Life Sciences) 
in accordance with the manufacturer’s protocol. Monocytes were 
then isolated from PBMCs using the Human Pan Monocyte 
Isolation Kit (Miltenyi Biotec) following manufacturer’s instruc-
tions (magnetic bead negative selection). Monocytes were then 
either fixed in 3% paraformaldehyde or differentiated into mono-
cyte-derived macrophages in culture. After 7 days in culture, 
macrophages were detached with trypsin and fixed in 3% para-
formaldehyde. Fixed cells were permeabilized using 0.2% Triton/
PBS (15 minutes incubation at room temperature), washed in 
0.2% Tween/PBS 3×, and blocked in 5% horse serum/PBS for 
20 minutes at room temperature. Samples were then incubated 
with the appropriate primary antibodies (Major Resources Table 
in the Data Supplement) for 30 minutes at room temperature, 
washed in 0.2% Tween/PBS 3× and for nonconjugated primary 
antibodies incubated with secondary antibodies for 30 min-
utes at room temperature protecting from light. After 3 washes 
in 0.2% Tween/PBS, the samples were resuspended in flow 
cytometry staining buffer (Biolegend) and acquired using a LSRII 
Cytofluorimeter (BD Biosciences).
Statistical Analysis
Values are expressed as mean±SEM. Group values were com-
pared using the computer program InStat (GraphPad Software, 
San Diego, CA). For the comparison of group means, a check 
was first made for normal distribution and similar variances: if 
this was passed, then an unpaired 2-sample 2-tailed Student t 
test was carried out. If the variances were significantly different, 
then an unpaired 2-sample 2-tailed t test with Welch correction 
was used. Statistical differences between monocytes/macro-
phages from the same preparation were analyzed by Student 
paired t test. For the comparison of multiple groups, an ANOVA 
test was used including assessment for both normal distribution 
and equal variance, and nonparametric tests deployed if data 
failed these tests, alongside Dunn multiple comparison post hoc 
test for between group analysis. To analyze linear relationships 
between two variables, a Pearson correlation test was used. To 
demonstrate the robust assessment of semiquantitative param-
eters such as plaque macrophage content and positivity for 
galectin-3, intra- and interobserver variability was determined 
by Bland-Altman plots. In all cases, statistical significance was 
concluded where the 2-tailed probability was <0.05.
RESULTS
Galectin-3–Negative Macrophages Accumulate 
in Human, Rabbit, and Mouse Advanced 
Atherosclerotic Plaques
Galectin-3 (Mac-2) is commonly used as a pan-macro-
phage marker, particularly in mouse studies, but we have 
observed that in human plaques, a third of macrophages 
(CD68 positive) do not express discernible galectin-3 pro-
tein expression (Figure 1A)—accepting the limitations in 
using CD68 as a macrophage marker revealed through 
recent cell-lineage experiments in mice.33,34 Moreover, after 
dichotomizing human coronary plaques into stable and 
unstable phenotypes, we observed a significant increase 
in the proportion of CD68-positive, galectin-3–negative 
macrophages within unstable plaques compared with sta-
ble lesions (1.9-fold; P<0.001; Figure 1A). Similarly, within 
rabbit aortic plaques, the percentage of galectin-3–neg-
ative macrophages (RAM-11 positive) was markedly 
increased within advanced atherosclerotic lesions of both 
sexes (3-fold; P<0.05; Figure 1B). Through cholesterol 
withdrawal, aortic atherosclerotic lesions transition toward 
a stable phenotype characterized by augmented VSMC-
to-macrophage ratio (Figure II in the Data Supplement), 
which was associated with a reduction in galectin-3–neg-
ative macrophage number (50%; P<0.05; Figure 1B), 
comparable to that observed in early lesions.
In agreement, marginal numbers of galectin-3–nega-
tive macrophages (CD68 positive) were detected within 
early Apoe−/− mouse brachiocephalic artery plaques but 
significantly increased in response to prolonged high-fat 
feeding. Indeed, Apoe−/− mice fed high fat for 26 or 36 
weeks exhibited a 2.4-fold increase in the percentage of 
galectin-3–negative macrophages (P<0.001; Figure 1C), 
accounting for 85% of all CD68-positive macrophages. 
In line with the plaque regression data obtained from 
the rabbit, statin treatment of high fat–fed Apoe−/− mice 
reduced intraplaque accumulation of galectin-3–neg-
ative macrophages in comparison to untreated control 
animals (63%; P<0.001; Figure 1D). It is plausible that 
the galectin-3–negative cells are VSMCs, which coex-
press CD68, but no evidence for this was detected within 
advanced human or mouse plaques (Figures III and IV in 
the Data Supplement). Our findings indicate that accrual 
of galectin-3–negative macrophages is associated with 
atherosclerosis progression in 2 diverse animal mod-
els of atherosclerosis and relate to an unstable plaque 
phenotype in humans; suggesting absence of galectin-3 
delineates a macrophage subset that is associated with 
atherosclerotic plaque progression and instability.
Galectin-3 Deficiency in Apoe−/− Mice Promotes 
an Advanced Plaque Phenotype
Given the above, we hypothesized that loss of galectin-3 
expression may drive atherosclerotic plaque progres-
sion. Indeed, a marked shift in pathological characteris-
tics associated with a more advanced plaque phenotype 
was observed in the absence of galectin-3 (Figure 2), 
as evidenced by an increase in CD68-positive area (1.7-
fold; P<0.01; Figure 2A) and necrotic/lipid core size 
(1.8-fold; P<0.05; Figure 2B) alongside a concomitant 
decrease in αSMactin-positive area (53%; P<0.05; Fig-
ure 2C) and collagen content (46%; P<0.01; Figure 2D). 
Such observations remained significant when quantified 
as total lesion area (Table I in the Data Supplement). 
Taken together, these findings indicate that galectin-3 
deficiency favors a less fibrotic and more inflamma-
tory plaque phenotype implying a protective role for 
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Figure 1. Galectin-3–negative macrophages accumulate in human, rabbit, and mouse advanced atherosclerotic plaques.
A, Representative images of smooth muscle cells (SM [smooth muscle]-actin), macrophages (CD [cluster of differentiation]-68), and galectin-3 
protein expression by immunohistochemistry and quantification from human stable and unstable coronary atherosclerotic plaques; n=14/group; 
***P<0.001; 2-tailed Student t test; scale bar in Ai equates to 1 mm and applies to Ai, Aii, Av, and Avi, scale bar in Aiii equates to 500 µm 
and applies to Aiii, Aiv, Avii, and Aviii. Black boxes in Aii and Avi represent areas at higher magnification in Aiii and Aiv and Avii and Aviii, 
respectively. Green arrows indicate regions containing galectin-3–positive macrophages, and red arrows indicate areas with  
galectin-3–negative macrophages. B, Representative images of a rabbit advanced plaque for macrophages (RAM [rabbit atherosclerosis 
macrophage]-11, in red) and galectin-3 (in green) protein expression by immunohistochemistry and quantification from male (blue bars) and 
female (red bars) rabbit early, advanced, and regressed atherosclerotic plaques; n=4/group; *P<0.05 compared with early plaques; #P<0.05 
compared with advanced plaques; Kruskal-Wallis nonparametric ANOVA; scale bar in Bi equates to 50 µm and applies to both panels. C, 
Representative images and quantification of macrophages (CD68, in red), galectin-3 (in green), and merged CD68/galectin-3 (in yellow) 
protein expression by immunohistochemistry from mouse brachiocephalic lesions from a time-course experiment where Apoe−/− mice were high-
fat fed for 12, 26, and 36 wk; n=10/group; ***P<0.001 compared with 12 wk; Kruskal-Wallis nonparametric ANOVA; scale bar in 12 wk panel 
equates to 100 µm and applies to all panels. D, Pharmacological-induced plaque regression experiment, where 9-wk high fat–fed Apoe−/− mice 
received pravastatin (40 mg/kg of body weight/day) within their drinking water (statin) or drinking water alone (control) during 9 wk further high-
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Figure 2. Galectin-3 deficiency in Apoe−/− mice promotes an advanced plaque phenotype.
Representative images and relative quantification of (A) macrophages (CD [cluster of differentiation]-68), (B) necrotic core (hematoxylin and 
eosin [H&E]; area encapsulated by dotted lines represents necrotic core), (C) vascular smooth muscle cell (VSMC; αSMactin [alpha-smooth 
muscle actin]), and (D) collagen (picrosirius red) from Lgals3−/−:Apoe−/− and Lgals3+/+:Apoe−/− male mouse brachiocephalic atherosclerotic 
lesions after 8 wk of high-fat feeding; n=13/group; *P<0.05, **P<0.01; 2-tailed Student t test. E, Representative images of elastin/van 
Gieson and quantification of plaque vulnerability index of Lgals3−/−:Apoe−/− and Lgals3+/+:Apoe−/− mouse brachiocephalic lesions; n=13/group; 
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Consistent with this, the vulnerability index of plaques 
from Lgals3−/−:Apoe−/− mice was markedly amplified com-
pared with their Lgals3+/+:Apoe−/− counterparts (3.5-fold; 
P<0.001; Figure 2E). However, it must be noted that ath-
erosclerotic plaque cross-sectional area was decreased 
within the brachiocephalic arteries of Lgals3−/−:Apoe−/− 
mice relative to control mice (39%; P<0.01; Table I in the 
Data Supplement), implying that galectin-3 deficiency 
produced smaller, less fibrotic, but more inflamed and 
advanced plaques.
Galectin-3 Retards Macrophage Accumulation 
and Invasion In Vitro and In Vivo
Macrophage buildup within atherosclerotic lesions is at 
least, in part, due to enhanced monocyte/macrophage 
Figure 3. Galectin-3 retards macrophage accumulation and invasion in vitro and in vivo.
Representative images of Matrigel-coated invasion Transwell inserts and quantification of in vitro macrophage invasion of (A) Lgals3−/− 
and Lgals3+/+ mouse monocyte-derived macrophages and (B) Lgals3−/− mouse monocyte-derived macrophages following the addition of 
mouse recombinant galectin-3 (5 nM); n=6/group; ***P<0.001; 2-tailed Student t test. C, Representative CD (cluster of differentiation)-68 
immunohistochemical-labeled images and quantification of macrophage density in an in vivo subcutaneous sponge invasion assay performed in 
Lgals3−/− and Lgals3+/+ male mice; n=6/group; ***P<0.001; 2-tailed Student t test. Scale bar in A equates to 50 µm and applies to all panels in 
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recruitment and is associated with the progression of 
plaques.35 As macrophage (CD68-positive cells) con-
tent was increased within plaques of galectin-3 mice, 
we assessed galectin-3 modulation on macrophage 
accumulation in vitro and in vivo, as a surrogate indica-
tor of steady-state invasion. The in vitro invasive capac-
ity of macrophages from Lgals3−/− mice was significantly 
increased in comparison to cells from Lgals3+/+ wild-type 
mice (2.2-fold increase; P<0.001; Figure 3A). Con-
versely, the number of invading Lgals3−/− macrophages 
was diminished through addition of exogenous recom-
binant galectin-3 compared with untreated cells (69%; 
P<0.001; Figure 3B). Furthermore, and consistent with 
our in vitro data, the number of macrophages recruited 
and accrued within implanted Matrigel-infused sponges 
was significantly increased within Lgals3−/− mice in com-
parison to Lgals3+/+ animals (1.6-fold increase; P<0.001; 
Figure 3C). These data support a key role for galectin-3 
in retarding macrophage invasive capacity and may 
explain the observed increase in (CD68 positive) macro-
phage numbers within brachiocephalic plaques of Lgals
3−/−:Apoe−/− mice.
Galectin-3 Antagonizes Generation of a 
Proinflammatory Macrophage Phenotype
To elucidate the potential mechanisms underlying the 
accumulation of galectin-3–negative macrophages 
during plaque progression, we evaluated the effect of 
galectin-3 knockdown in human macrophages on the 
expression of genes commonly associated with macro-
phage motility, accumulation, and polarization,36 includ-
ing MMPs proposed to play a role in atherosclerosis.6 
Utilizing small interfering RNA, we observed on average 
a 77% knockdown of LGALS3 (lectin, galactoside-bind-
ing, soluble, 3; galectin-3) mRNA expression in primary 
human macrophages (Figure V in the Data Supplement). 
Real-time quantitative PCR analysis revealed the mRNA 
expression of MMP1, 2, 8, 10, and 25 was not affected 
by galectin-3 knockdown, although MMP11 was signifi-
cantly reduced (64%; P<0.05; Figure 4A). Conversely, 
MMP12 mRNA expression was distinctly increased (3.5-
fold; P<0.05; Figure 4A). Accordingly, MMP12 protein 
expression was increased in macrophages subjected to 
galectin-3 silencing (1.4-fold; P<0.001; Figure 4B), sug-
gesting MMP12 plays a central role to the heightened 
invasive capacity observed in the galectin-3–negative, 
CD68-positive macrophage subpopulation. The expres-
sion of endogenous inhibitors of MMPs (TIMPs) was not 
affected by galectin-3 knockdown (Figure 4C). Moreover, 
galectin-3 knockdown induced overexpression of CCL2 
(2.3-fold; P<0.01; Figure 4D), suggesting that galectin-
3–negative macrophages are potentially able to promote 
or enhance further macrophage recruitment to devel-
oping atherosclerotic lesions. Additionally, we detected 
a clear shift toward a proinflammatory macrophage 
phenotype in response to galectin-3 silencing (Fig-
ure 4D), as mRNA expression of the proinflammatory 
molecules TNFA (tumor necrosis factor-alpha), PTGS2 
(prostaglandin-endoperoxide synthase 2; cyclooxygen-
ase-2), and IL-6 was increased in response to galectin-3 
depletion by 1.7-fold, 1.5-fold, and 2.8-fold, respectively 
(P<0.05; Figure 4D), implicating galectin-3 as a possible 
negative regulator of inflammation and proinflammatory 
macrophage polarization. The effects on IL-6 and CCL2 
(MCP-1) were confirmed at the protein level (P<0.05; 
Figure VI in the Data Supplement). A reciprocal decrease 
in genes associated with M2 macrophage polarization 
(IL10, CD163, and MRC1 [mannose receptor C-type 
1]) was not observed between macrophages subjected 
to galectin-3 knockdown and control cells (Figure 4E). 
Interestingly, polarization of macrophages to a proinflam-
matory state with GM-CSF37 was associated with loss 
of galectin-3 membrane expression when compared 
with M-CSF polarized macrophages (68%; P<0.01; Fig-
ure VII in the Data Supplement), which was prevented 
in the presence of exogenous TGFβ1. M-CSF–directed 
and GM-CSF–directed macrophage polarization dif-
ferentially affects MMP12 mRNA levels and is asso-
ciated with the generation of morphologically distinct 
phenotypes.38 We confirmed that GM-CSF polarization 
of human macrophages increased MMP12 mRNA and 
protein expression (Figure VIII in the Data Supplement). 
Also, after magnetic-bead cell separation, we observed 
that galectin-3 expression defines a subpopulation of 
macrophages through assessment of cell morphology. 
Galectin-3–negative macrophages show a rounded mor-
phology, whereas the galectin-3–positive subpopulation 
displays a more elongated shape (Figure IX in the Data 
Supplement). It is plausible that galectin-3 expression is 
already altered within circulating monocytes and delin-
eates their phenotype; however, flow cytometry analysis 
revealed that most circulating human monocytes (80%) 
are galectin-3 positive and are not stratified through 
expression of CCR2 (chemokine [C-C motif] receptor 
2)—a known marker of proinflammatory monocytes (Fig-
ure X in the Data Supplement). Furthermore, upon 2 
hours adhesion in vitro, most cells display cell-surface 
expression of galectin-3 and CCR2 (Figure X in the 
Data Supplement). Similar observations were also made 
by immunocytochemical assessment (Figure XI in the 
Data Supplement). However, flow cytometry on GM-CSF 
polarized monocyte-derived macrophages revealed 43% 
are galectin-3 negative (Figure XII in the Data Supple-
ment). Taken together, the findings imply the loss of 
galectin-3 occurs after monocytes have differentiated 
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Galectin-3 Regulation of TGFβ Signaling 
Attenuates Macrophage Invasion
It has been proposed that the galectin-3 and TGFβ sig-
naling pathways coordinate during profibrotic and anti-
inflammatory responses.39 In agreement, macrophages 
subjected to galectin-3 silencing displayed reduced 
TGFB1 gene (20%; P<0.05) and protein expression 
(55%; P<0.05) when compared with controls (Figure 5A 
and 5B, respectively). In addition, SMAD-3 phosphory-
lation was also markedly reduced in macrophages with 
suppressed galectin-3 expression (64%; P<0.01; Fig-
ure 5C) while total SMAD-3 levels were unaffected 
(Figure XIII in the Data Supplement), suggesting auto-
crine TGFβ signaling is regulated, in part, by galectin-3. 
In accordance with our data from macrophages with 
Figure 4. Galectin-3 antagonizes generation of a proinflammatory macrophage phenotype.
LGALS3 (lectin, galactoside-binding, soluble, 3) mRNA expression was silenced for 48 h in human monocyte-derived macrophages, scrambled 
AllStars oligonucleotides served as a control. A, Quantitative polymerase chain reaction (qPCR) for MMP (matrix metalloproteinase)-1, 2, 8, 
10, 11, 12, 14, and 25 mRNA expression; n=4/group; *P<0.05; 2-tailed Student t test. B, Representative Western blot images and relative 
quantification of MMP12 protein levels in human monocyte-derived macrophages; n=4/group; ***P<0.05; 2-tailed Student t test. Stain-free 
control is shown as a loading control (LC). Real-time qPCR for TIMP (tissue inhibitor of metalloproteinase) mRNA (C), proinflammatory markers 
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Figure 5. Galectin-3 regulates macrophage TGF (transforming growth factor)-β signaling and dampens polarization of 
proinflammatory macrophages and their accumulation within atherosclerotic lesions.
A, Real-time quantitative polymerase chain reaction (RT-qPCR) for TGFB1 mRNA expression and (B) Western blotting for active TGFβ1 
protein expression, in human monocyte-derived macrophages after LGALS3 gene silencing; n=4/group; *P<0.05; 2-tailed Student t test. C, 
Representative Western blot image and relative quantification of phospho-SMAD3 (mothers against decapentaplegic homolog 3) protein levels 
in human monocyte-derived macrophages after LGALS3 gene silencing; n=4/group; **P<0.01; 2-tailed Student t test. A free-stain control is 
shown as a loading control (LC) in both B and C. RT-qPCR for MMP (matrix metalloproteinase)-12 (D), CCL2 (chemokine [C-C motif] ligand 
2; E), and PTGS2 (prostaglandin-endoperoxide synthase 2; F) in human monocyte-derived macrophages after the addition of recombinant 
human TGFβ1 (0.2 ng/mL) for 24 h; n=4/group; *P<0.05, **P<0.01; 2-tailed Student t test. G, Quantification of in vitro macrophage invasion 
assay. Monocyte-derived human macrophages were allowed to invade through Matrigel-coated insert for 48 h in the presence of mouse 
IgG (1 µg/mL), recombinant human TGFβ1 (0.2 ng/mL), or TGFβ1 blocking neutralizing antibody (NAb; 1 µg/mL), following LGALS3 (lectin, 
galactoside-binding, soluble, 3) silencing; n=4/group; *P<0.05 vs controls, $P<0.05 vs si-Gal-3; Kruskal-Wallis nonparametric ANOVA. 
H–L, Representative images and relative quantification of (H) TGFβ1, (I) phospho-SMAD3, (J) MMP12, (K) CCL2, and (L) PTGS2 protein 
expression by immunohistochemistry in Lgals3−/−:Apoe−/− and Lgals3+/+:Apoe−/− male mouse brachiocephalic atherosclerotic lesions after 8 wk 
of high-fat feeding; n=13/group; *P<0.05, **P<0.01; 2-tailed Student t test. Scale bar in H equates to 200 µm and applies to panels in H and 
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Figure 6. Galectin-3 can be cleaved by MMP (matrix metalloproteinase)-12 indicating a potential novel regulatory mechanism.
A, Representative Western blot images and quantification of human recombinant galectin-3. A cleaved fragment of 22 kDa can be visualized 
in response to coincubation with human recombinant MMP12 (100 nM); n=4/group; *P<0.05 compared with control and pro-MMP12, and 
#P<0.05 compared with active MMP12; Kruskal-Wallis nonparametric ANOVA. B, Representative Western blot images and quantification 
of galectin-3 protein levels in conditioned media from human monocyte-derived macrophages treated with either human recombinant TIMP 
(tissue inhibitor of metalloproteinase)-3 (10 nM) or a broad-spectrum MMP inhibitor BB94 (20 nM); n=4/group; *P<0.05, **P<0.01; 
2-tailed Student t test. C, Quantification of galectin-3 plasma levels in atherosclerotic Mmp12+/+:Apoe−/− and Mmp12−/−:Apoe−/− male mice 
assessed by ELISA assay, which identifies both full-length and cleaved galectin-3 fragments; n=8/group; *P<0.05; 2-tailed Student t test. 
Quantification of (D) macrophages (CD [cluster of differentiation]-68 positive cells) and (E) galectin-3–positive macrophages, as assessed by 
immunohistochemistry, within brachiocephalic atherosclerotic plaques from Mmp12+/+:Apoe−/− and Mmp12−/−:Apoe−/− male mice; n=10/group; 
*P<0.05; 2-tailed Student t test. F, Correlation of MMP12-positive macrophages and galectin-3–positive macrophages in human coronary 
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galectin-3 knockdown, evidence exists indicating that 
MMP12, CCL2, and PTGS2 (Figure 2) expression can 
be inhibited by TGFβ1.40–42 Supportingly, we observed 
that MMP12, CCL2, and PTGS2 gene expression were 
significantly reduced in response to TGFβ treatment in 
proinflammatory macrophages by 26% (P<0.05; Fig-
ure 5D), 36% (P<0.05; Figure 5E), and 98% (P<0.01; 
Figure 5F), respectively. Taken together, these data 
indicate that galectin-3 regulates macrophage invasive 
capacity, in part, through the regulation of TGFβ signaling. 
To further test this hypothesis, we evaluated the effect of 
disrupting TGFβ signaling or galectin-3 on the ability of 
macrophages to invade through a synthetic matrix in vitro. 
In line with our hypothesis, TGFβ1 neutralization signifi-
cantly increased macrophage invasion through Matrigel 
in the presence of endogenous levels of galectin-3 (8.2-
fold; P<0.05; Figure 5G), whereas exogenous TGFβ1 
had no effect on cell invasion (Figure 5G). However, the 
enhanced invasion observed in macrophages subjected 
to galectin-3 knockdown (11.3-fold; P<0.05; Figure 5G) 
was significantly abrogated by addition of exogenous 
TGFβ1 (64%; P<0.05; Figure 5G), while TGFβ1 neutral-
ization was ineffective (Figure 5G), excluding an additive 
or synergistic effect and supporting a role for galectin-3 
in negatively regulating macrophage invasion through 
preservation of TGFβ expression and subsequent sig-
naling. Such beneficial effects may be afforded through 
galectin-3–mediated retention of TGFβ receptors at the 
cell surface. Indeed, we reveal that silencing of galec-
tin-3 in human macrophages results in loss of membrane 
TGFβRI expression (89%; P<0.01; Figure XIV in the 
Data Supplement).
Galectin-3 Deficiency Promotes Accumulation 
of Proinflammatory Macrophages Within 
Atherosclerotic Lesions
To substantiate our in vitro findings and corroborate 
that galectin-3–positive macrophages exhibit a profi-
brotic anti-inflammatory phenotype in vivo, we performed 
immunohistological analysis of atherosclerotic plaques, 
which revealed that the percentage of TGFβ1-positive 
macrophages was reduced in plaques from Lgals3−/−:A
poe−/− mice compared with their Lgals3+/+:Apoe−/− coun-
terparts (66%; P<0.001; Figure 5H). Accordingly, mac-
rophage SMAD-3 phosphorylation was also reduced 
within lesions of Lgals3−/−:Apoe−/− mice (71%; P<0.001; 
Figure 5I) compared with wild-type controls, confirm-
ing reduced activation of the TGFβ signaling pathway 
in the absence of galectin-3. Furthermore, the percent-
age of MMP12-, CCL2-, and PTGS2-positive macro-
phages within the atherosclerotic plaques of Lgals3−/−:A
poe−/− mice was increased 2.9-fold (P<0.01; Figure 5J), 
1.7-fold (P<0.01; Figure 5K) and 1.5-fold (P<0.05; Fig-
ure 5L), respectively, when compared with Lgals3+/+:A
poe−/− controls. Together, these findings strongly indicate 
that galectin-3 acts as a negative regulator of inflam-
mation by modulating TGFβ signaling and reducing the 
expression of the proinflammatory molecules MMP12, 
CCL2, and PTGS2 in a mouse model of atherosclerosis.
Galectin-3 Can Be Cleaved by MMP12 
Indicating a Potential Feedback Mechanism
Galectin-3 presents within its structure collagen-like 
repeats, which are susceptible to proteolytic cleavage by 
MMPs, resulting in the generation of a soluble fragment 
≈22 kDa in size. Considering the observed increased mac-
rophage expression of MMP12 in response to galectin-3 
deficiency/knockdown, we propose a novel mechanism 
where following the reduction of galectin-3 expression 
and consequent increase in MMP12 production in mac-
rophages, MMP12-mediated cleavage of galectin-3 can 
shift macrophages toward a proinflammatory state and 
reduce their profibrotic nature. In agreement with our 
hypothesis, coincubation of recombinant galectin-3 and 
active MMP12 resulted in a significant increase in accu-
mulation of a cleaved 22-kDa fragment detectable by 
Western blot (15.8-fold; P<0.05; Figure 6A). Moreover, 
the production of the 22-kDa fragment could be retarded 
by addition of exogenous TIMP3 (70%; P<0.05; Fig-
ure 6A). Equally, the presence of the 22-kDa fragment 
within conditioned media of macrophages was reduced 
by supplementation with either recombinant TIMP3 
(71%; P<0.05; Figure 6B) or a broad-spectrum inhibitor 
of MMPs, BB94 (70%; P<0.01; Figure 6B), which was 
associated with augmented TGFβ1 protein expression 
(P<0.05; Figure XV in the Data Supplement). Further-
more, plasma levels of soluble galectin-3 were signifi-
cantly lower in atherosclerotic Mmp12−/−:Apoe−/− mice, 
compared with their wild-type controls (13%; P<0.05; 
Figure 6C), supporting the hypothesis that MMP12 con-
tributes to galectin-3 cleavage and release of a circula-
tory soluble fragment. To determine whether our findings 
translate in vivo, we assessed macrophage galectin-3 
expression within plaques of Mmp12−/−:Apoe−/− mice 
and wild-type controls. Although positivity of the mac-
rophage marker CD68 was reduced within brachioce-
phalic plaques of Mmp12−/−:Apoe−/− mice (63%; P<0.05; 
Figure 6D), a significant increase in relative galectin-3 
positivity was observed (1.6-fold; P<0.05; Figure 6E). 
We also observed an inverse correlation between the 
number of MMP12-positive and galectin-3–positive 
macrophages (CD68 positive) in advanced human coro-
nary plaques (r2=0.5003; P<0.0001; Figure 6F). Taken 
together, these data suggest a possible novel mechanism 
where MMP12 could promote a proinflammatory state 
in adjacent macrophages through cleavage of galec-
tin-3 and blocking the profibrotic response attributed to 
galectin-3–positive macrophages. This may, in part, be 
through galectin-3–mediated preservation of TGFβR 
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MMP12 to human macrophages induced marked loss of 
membrane TGFβRI expression (97%; P<0.001; Figure 
XIV in the Data Supplement).
DISCUSSION
Galectin-3 (also known as Mac-2) is commonly used as 
a pan-macrophage marker in many studies, and primar-
ily because of this, galectin-3 expression is associated 
with plaque development and progression. However, our 
current findings suggest that galectin-3 may not serve 
as a reliable pan-macrophage marker. We reveal that 
a subpopulation of macrophages, which express neg-
ligible levels of galectin-3, exist within human, rabbit, 
and mouse atherosclerotic lesions and overwhelmingly 
accumulate in advanced plaques. Such lesions display 
a deleterious shift in cellular and extracellular compo-
nents, implying that galectin-3–negative macrophages 
are associated with plaque instability. Indeed, atheroscle-
rotic plaque stability is normally achieved through main-
tenance of a protective fibrous cap, promoted through 
augmented collagen deposition, reduced collagen deg-
radation, reduced proinflammatory cytokine production, 
and diminished macrophage accumulation and associ-
ated protease release.1,43 Our in vitro and in vivo stud-
ies demonstrate that galectin-3–positive macrophages 
associate with atheroprotective mechanisms. Indeed, our 
knockout mouse studies show that galectin-3 promotes 
a plaque phenotype exhibiting characteristics associ-
ated with increased stability. Moreover, we consistently 
observe that galectin-3 expression within CD68-positive 
cells (which we deem macrophages) is adversely dimin-
ished as plaques advance but are maintained in mouse 
plaque regression models, replicating observations in 
human atherosclerosis.44
Interestingly, although plaque area was decreased 
within brachiocephalic arteries of mice lacking galec-
tin-3, an adverse shift in cellular and extracellular com-
ponents was evident. This finding implies that although 
the profibrotic effects of galectin-3 can contribute to 
plaque mass and volume, importantly, the composition of 
the lesion is favorably altered and infers increased stabil-
ity. Other studies also conducted in Apoe-deficient mice 
have similarly shown that plaque size or plaque volume 
(referring to the surface of an artery covered in athero-
matous lesions) is reduced within aortic regions and the 
brachiocephalic artery of galectin-3–deficient mice.14,17 
However, plaque area within the aortic root of C57BL/6J 
mice deficient for galectin-3 was increased compared 
with wild-type controls, and lesions were deemed more 
complex, although in-depth analysis of compositional 
parameters was not reported.16 Nonetheless, a proath-
erosclerotic role has been ascribed to galectin-3 due to a 
positive association with increased plaque area compared 
with deficient animals. However, neither plaque burden 
nor size serve as strong predictors of clinical symptoms, 
and therapies such as statins that substantially reduce 
adverse cardiovascular complications related to plaque 
instability exert only modest effects on plaque volume but 
dramatically alter composition, particularly inflammation- 
and fibrous-related elements.45 Furthermore, the PROS-
PECT trial (Providing Regional Observations to Study 
Predictors of Events in the Coronary Tree) revealed that 
identification of a thin-cap fibroatheroma before treat-
ment serves as the best predictor and surrogate marker 
of a vulnerable plaque, and the composition of thin-cap 
fibroatheromas is attributed to increased inflammation 
and reduced plaque fibrosis.46 Our data presented here 
demonstrate that although loss of galectin-3 results in 
smaller plaques, they exhibit a more advanced plaque 
phenotype evidenced by increased inflammation and 
necrotic core expansion alongside decreased collagen 
and smooth muscle cell content. Supportingly, compari-
son of aortic sinus plaques in high fat–fed C57BL/6J 
mice with and without galectin-3 deletion revealed the 
presence of macrophage galectin-3 correlated with 
reduced intraplaque macrophage content.47
Macrophage accumulation within atherosclerotic 
plaques is reliant on their invasive capacity alongside 
their chemotactic responsiveness and proteolytic activ-
ity.5 Galectin-3 has been proposed as a chemotactic 
molecule for macrophages.48 However, we show that 
macrophage loss of galectin-3 enhances their invasive 
capacity and accumulation within plaques, which has also 
been inferred by others.16 Galectin-3 promotes cell-cell 
and cell-matrix adhesion,49 which fits with it exerting an 
anti-invasive effect, suggesting cleavage of galectin-3 is 
required to liberate macrophages and facilitate invasion. 
Relatedly, we observed macrophage MMP12 expression 
was suppressed by galectin-3, while plaques from galec-
tin-3–deficient mice amassed more MMP12-positive 
macrophages. Similarly, an inverse correlation between 
macrophage expression of galectin-3 and MMP12 was 
observed in advanced human lesions. Accumulating evi-
dence demonstrates macrophage MMP12 expression is 
elevated within advanced human,50,51 mouse,52 and rab-
bit plaques53; promotes the invasive capacity of macro-
phages52,54; and adversely affects plaque composition 
and stability.27,52,53,55 We, therefore, propose that macro-
phage galectin-3 expression retards macrophage inva-
sion and associated plaque progression, in part, through 
suppression of MMP12 expression, while an increase in 
MMP12 expression and activity (through GM-CSF stim-
ulation, for example) can result in cleavage of galectin-3 
and adversely modulate macrophage invasion.
TGFβ1 can potently inhibit macrophage MMP12 
expression through an SMAD-2/3–dependent mecha-
nism.40 Notably, galectin-3 expression is linked with 
increased TGFβ1 expression and signaling, and subse-
quent promotion of fibrosis,56–58 potentially through retain-
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provide evidence that macrophage membrane TGFβR1 
expression is reduced through galectin-3 knockdown or 
heightened MMP12 activity. In support, Papaspyridonos 
et al13 demonstrated increased TGFβR1 expression after 
galectin-3 addition to human macrophages. TGFβ signal-
ing is considered to favor atherosclerotic plaque stability 
through promoting plaque fibrosis59 alongside blunting 
macrophage expression of proinflammatory genes.60 Our 
findings show similar characteristics are observed when 
macrophages express marked galectin-3. We, therefore, 
propose galectin-3 expression delineates an anti-inflam-
matory and profibrotic macrophage phenotype, which 
displays a galectin-3–TGFβ1 mechanism. This process 
is propagated by autoinduction of TGFβ161,62 and can be 
interrupted by MMP12. In support, studies utilizing sin-
gle-cell analysis of macrophages have indicated galec-
tin-3 expression delineates macrophage subsets within 
murine atherosclerotic arteries, which do not overtly over-
lap with proinflammatory-associated gene expression 
profiles.63,64 Moreover, single-cell RNA sequencing sug-
gested that galectin-3–positive macrophage populations 
persisted during mouse atherosclerotic plaque regres-
sion while more proinflammatory subsets receded,64 in 
line with our own findings.
Elevated circulating levels of galectin-3 correlate 
with early myocardial infarction, predict long-term car-
diovascular death in high-risk patients with coronary 
artery disease,65 and serve as an independent indica-
tor of increased risk of all-cause mortality in patients 
after myocardial infarction,66 suggesting that galectin-3 
within the circulation is a biomarker of cardiovascular 
disease. It is notable that galectin-3 lacks a classical 
signal sequence required for protein translocation to the 
endoplasmic reticulum/Golgi complex and subsequent 
secretion,49 implying proteolytic cleavage of galectin-3 
from macrophages and subsequent release into the cir-
culation underlies its observed increase in cardiovascular 
disease. Indeed, we detected negligible amounts of full-
length galectin-3 released from human macrophages, 
whereas a cleaved fragment readily accumulated within 
condition media, which is dependent upon the activity 
of MMPs including MMP12. Relatedly, cleaved galec-
tin-3 has been reported as a novel surrogate marker for 
MMP activity in growing breast cancers.67 We, therefore, 
postulate that MMP12 can target and cleave galec-
tin-3 promoting an antifibrotic response and perpetuat-
ing inflammation. Consequently MMP12 cleavage may 
underlie the increased circulating levels of galectin-3 
observed in patients with cardiovascular diseases, par-
ticularly given that commercially available ELISAs for 
galectin-3 do not discriminate between full-length and 
cleaved forms of galectin-3. Supporting this proposition, 
MMP12 does not colocalize within galectin-3–positive 
macrophages within plaques while the number of galec-
tin-3–positive macrophages is increased within lesions 
from Mmp12−/−:Apoe−/− mice. Concomitantly, we report 
reduced circulating galectin-3 levels within the plasma 
of atherosclerotic Mmp12−/−:Apoe−/− mice compared with 
animals with functional MMP12, independent of plaque 
size and macrophage content.
Previous evidence revealed human carotid plaques 
contain up to 25% of macrophages that are galectin-3 
negative,12 and single-cell RNA sequencing highlighted 
galectin-3 favors a discrete macrophage population.63,64 
A key question is how increased MMP12 expression 
alongside loss of galectin-3 is induced within a subset of 
macrophages. Morphologically, we observed that galectin-
3–positive macrophages are predominantly elongated, 
whereas galectin-3–negative macrophages are rounded 
in shape, with similar observations reported for M-CSF–
directed and GM-CSF–directed macrophages, respec-
tively.38 Pertinently, GM-CSF polarized macrophages 
display heightened MMP12 expression compared with 
their M-CSF counterparts.38 Intriguingly, galectin-3 can 
dampen GM-CSF–induced monocyte/macrophage pro-
liferation and suppress GM-CSF–related gene transcrip-
tion.68 Our previous data demonstrated a detrimental role 
for macrophage MMP12 expression in atherosclerotic 
plaque progression.27,51,52 Additional evidence has shown 
that CSF (colony stimulating factor) regulation of proteol-
ysis plays a prominent role in the proatherosclerotic pro-
gramming of macrophages.23,25 We, therefore, postulate 
GM-CSF regulation of MMP12 may modulate macro-
phage galectin-3 expression and its associated protec-
tive effects on atherosclerosis. Indeed, we demonstrate 
that in opposition to M-CSF polarized macrophages, 
GM-CSF differentiated macrophages display loss of 
membrane galectin-3, which can be restored through 
addition of TGFβ1. In association, MMP12 activity pro-
motes loss of macrophage membrane TGFβR1 expres-
sion on M-CSF macrophages, demonstrating a dual 
deleterious effect of MMP12 on macrophage galectin-3 
expression and associated TGFβ signaling. In relation to 
the arterial wall, while M-CSF is constitutively expressed 
by endothelial cells, VSMCs, and macrophages, GM-CSF 
induction requires proinflammatory stimuli such as TNFα 
or IL-1.69 As such, inflamed advanced plaques would be 
expected to display increased GM-CSF expression (as 
we have shown previously25) and potentially regulate 
the associated increased macrophage expression of 
MMP12 and concomitant loss of membrane galectin-3.
There are some limitations associated with our find-
ings. We have used CD68 as a pan-macrophage marker, 
which itself has recently been questioned as cell-lin-
eage approaches demonstrated phenotypically modu-
lated VSMCs acquire CD68 expression within mouse 
lesions,33,34 and possibly human plaques.70 Similarly, we 
have deployed SM actin as a marker of VSMCs, and 
cell-lineage experiments in mice have shown VSMCs 
can lose SM actin expression within murine plaques.34 
Accordingly, considering the concerns associated with 
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macrophage derived versus SMC derived, we cannot 
definitively state that the galectin-3–negative cells within 
our in vivo studies are indeed macrophages. Addition-
ally, it is plausible that galectin-3–negative macrophages 
originate from differing monocyte precursors; however, 
galectin-3 expression was detected on monocytes and 
not delineated by the proinflammatory monocyte marker 
CCR2. Moreover, upon adherence, most monocytes dis-
play galectin-3 protein expression, supporting the propo-
sition that loss of macrophage galectin-3 expression is 
orchestrated within tissues, rather than the accumula-
tion of divergent monocyte subsets. While our original 
evidence demonstrates MMP12 can cleave galectin-3, 
other MMPs are also capable of galectin-3 cleavage,71,72 
including MMP7,73 which also colocalizes with MMP12 in 
a subset of macrophages within advanced human athero-
sclerotic plaques.50 Finally, to ensure the reliability of our 
semiquantitative assessment of histological parameters, 
intra- and interobserver coefficients were nonsignificant, 
demonstrating that the difference between measure-
ments was within the limits of agreement (Figure XVI in 
the Data Supplement), as demonstrated previously.23
In conclusion, we highlight a profibrotic role for 
galectin-3 in atherosclerosis. Our findings indicate that 
galectin-3–negative macrophages accumulate within 
rabbit, mouse, and human advanced plaques and show 
loss of galectin-3 is directly associated with detrimental 
plaque composition in a mouse model of atherosclerosis. 
We demonstrate that diminished macrophage galectin-3 
expression promotes an invasive proinflammatory phe-
notype, characterized by reduced TGFβ signaling and 
heightened MMP12 levels. Lastly, we propose a novel 
mechanism by which MMP12 might perpetuate inflam-
mation through galectin-3 cleavage, generating the 
galectin-3–negative population observed in our studies 
(Figure XVII in the Data Supplement). Collectively, these 
findings delineate galectin-3 as a negative regulator of 
inflammation and macrophage invasion that opposes 
adverse atherosclerosis progression and confirms 
MMP12 as a potential target for medical intervention of 
atherosclerosis.
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